Since our founding in 2011, we have been privileged to have the support of Flagship Pioneering, notable institutional investors in the U.S., Europe and Asia, our strategic pharmaceutical and biotech collaborators and other private investors. As of December 2016, Moderna has raised over $1.1 billion from equity financings. Our financial partners share our enthusiasm for the promise of mRNA science and have provided the necessary support for Moderna to execute on our ambitious strategy and deliver a new class of mRNA medicines for patients. Below are a sample of the institutional investors that support Moderna.